CARDIFF ONCOLOGY INC (CRDF) Forecast, Price Target & Analyst Ratings

NASDAQ:CRDF • US14147L1089

Current stock price

1.8 USD
+0.11 (+6.51%)
At close:
1.83 USD
+0.03 (+1.67%)
After Hours:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for CARDIFF ONCOLOGY INC (CRDF).

Forecast Snapshot

Consensus Price Target

Price Target
$8.74
+ 385.71% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
Apr 30, 2026
Period
Q1 / 2026
EPS Estimate
-$0.14
Revenue Estimate
86.7K
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
81.43%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$8.74
Upside
+ 385.71%
From current price of $1.80 to mean target of $8.74, Based on 14 analyst forecasts
Low
$3.54
Median
$10.20
High
$12.60

Price Target Revisions

1 Month
-17.38%
3 Months
-19.46%

Price Target Summary

14 Wall Street analysts provided a forecast for the next 12 months for CRDF. The average price target is 8.74 USD. This implies a price increase of 385.71% is expected in the next year compared to the current price of 1.8.
The average price target has been revised downward by 19.46% in the past 3 months.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

CRDF Current Analyst RatingCRDF Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 2 4 6 8

Analyst Ratings History

CRDF Historical Analyst RatingsCRDF Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 5 10

Analyst Ratings Consensus

ChartMill Buy Consensus
81.43%
CRDF was analyzed by 14 analysts. The buy percentage consensus is at 81. So analysts seem to be very confident about CRDF.
In the previous month the buy percentage consensus was at a similar level.
CRDF was analyzed by 14 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2026-02-25Piper SandlerMaintains Overweight -> Overweight
2026-01-28HC Wainwright & Co.Reiterate Buy -> Buy
2025-08-06HC Wainwright & Co.Maintains Buy -> Buy
2025-07-08Ladenburg ThalmannInitiate Buy
2025-06-24JefferiesInitiate Hold
2025-05-09HC Wainwright & Co.Maintains Buy -> Buy
2025-02-28HC Wainwright & Co.Maintains Buy -> Buy
2024-12-13Piper SandlerMaintains Overweight -> Overweight
2024-11-08HC Wainwright & Co.Maintains Buy -> Buy
2024-09-06Craig-HallumInitiate Buy
2024-05-06HC Wainwright & Co.Reiterate Buy -> Buy
2024-03-06HC Wainwright & Co.Maintains Buy -> Buy
2024-03-01Piper SandlerMaintains Overweight -> Overweight
2023-08-11HC Wainwright & Co.Maintains Buy -> Buy
2023-08-08HC Wainwright & Co.Maintains Buy -> Buy
2023-05-09HC Wainwright & Co.Maintains Buy
2023-03-29HC Wainwright & Co.Reiterate Buy
2023-03-07HC Wainwright & Co.Maintains Buy
2022-09-16HC Wainwright & Co.Maintains Buy
2022-09-13Piper SandlerMaintains Overweight
2022-08-29BairdMaintains Outperform
2022-05-09HC Wainwright & Co.Maintains Buy
2022-02-28HC Wainwright & Co.Maintains Buy
2021-12-08BairdInitiate Outperform
2021-08-10HC Wainwright & Co.Maintains Buy

Next Earnings Forecast Details

Next Earnings Details

Release Date
Apr 30, 2026
Period
Q1 / 2026
EPS Estimate
-$0.14
Revenue Estimate
86.7K
Revenue Q2Q
-20.46%
EPS Q2Q
31.34%
Number of Analysts
10

Next Earnings Revisions

Revenue (1 Month)
0.00%
Revenue (3 Months)
6.25%
EPS (1 Month)
0.00%
EPS (3 Months)
25.41%

Next Earnings Summary

CRDF is expected to report earnings on 4/30/2026. The consensus EPS estimate for the next earnings is -0.14 USD and the consensus revenue estimate is 86.70K USD.
The next earnings revenue estimate has been revised upward by 6.25% in the past 3 months. Upward revisions are a positive sign and indicate that analysts are more optimistic about the next earnings compared to 3 months ago.
→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2026 - 2033

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033
Revenue
YoY % growth
CRDF revenue by date.CRDF revenue by date.
488K
25.13%		683K
39.96%		593K
-13.18%		408.724K
-31.08%		251.359K
-38.50%		102K
-59.42%		110.14M
107,880.39%		344.37M
212.67%		714.62M
107.52%		1.075B
50.43%		1.465B
36.28%
EBITDA
YoY % growth
CRDF ebitda by date.CRDF ebitda by date.
-45.014M
-13.50%		-48.247M
-7.18%		-48.596M
-0.72%		N/AN/AN/AN/AN/AN/AN/AN/A
EBIT
YoY % growth
CRDF ebit by date.CRDF ebit by date.
-45.412M
-13.81%		-48.651M
-7.13%		-48.96M
-0.64%		-50.647M
-3.45%		-69.45M
-37.12%		-124.461M
-79.21%		-111.729M
10.23%		-8.097M
92.75%		377.3M
4,759.50%		720.04M
90.84%		1.097B
52.35%
Operating Margin
CRDF operating margin by date.CRDF operating margin by date.
-9,305.74%-7,123.13%-8,256.32%-12,391.51%-27,629.70%-122,020.60%-101.44%-2.35%52.80%66.98%74.88%
EPS
YoY % growth
CRDF eps by date.CRDF eps by date.
-0.93
-4.49%		-0.95
-2.15%		-0.69
27.37%		-0.60
12.83%		-0.79
-32.07%		-1.15
-45.02%		-1.21
-4.93%		-0.08
93.25%		0.57
800.00%		1.46
155.36%		2.31
58.04%

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q1 / 26 Q2 / 26 Q3 / 26 Q4 / 26 Q1 / 27 Q2 / 27 Q3 / 27 Q4 / 27 Q1 / 28 Q2 / 28 Q3 / 28 Q4 / 28
EPS
Q2Q % growth		-0.14
31.34%		-0.14
35.04%		-0.15
14.65%		-0.16
-42.46%		-0.21
-53.51%		-0.22
-64.49%		-0.23
-59.35%		-0.24
-56.22%		-0.28
-30.64%		-0.32
-40.91%		-0.34
-45.59%		-0.35
-41.67%
Revenue
Q2Q % growth		86.7K
-20.46%		88.403K
-26.94%		90.097K
-24.92%		93.503K
-61.52%		84.997K
-1.96%		84.997K
-3.85%		84.997K
-5.66%		84.997K
-9.10%		N/AN/AN/AN/A
EBITDA
Q2Q % growth		N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
EBIT
Q2Q % growth		-11.096M
22.85%		-11.799M
20.15%		-12.802M
-6.92%		-14.103M
-80.18%		-18.768M
-69.15%		-19.788M
-67.71%		-20.808M
-62.53%		-21.318M
-51.16%		N/AN/AN/AN/A

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

CRDF Yearly Revenue VS EstimatesCRDF Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 500M 1B
CRDF Yearly EPS VS EstimatesCRDF Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 -20 -40 -60 -80

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
-18.63%
EPS Next 5 Year
13.48%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
-39.74%
Revenue Next 5 Year
274.72%

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

CARDIFF ONCOLOGY INC / CRDF Forecast FAQ

Can you provide the average price target for CARDIFF ONCOLOGY INC stock?

14 analysts have analysed CRDF and the average price target is 8.74 USD. This implies a price increase of 385.71% is expected in the next year compared to the current price of 1.8.

What is the next earnings date for CRDF stock?

CARDIFF ONCOLOGY INC (CRDF) will report earnings on 2026-04-30, after the market close.

Can you provide the consensus estimates for CARDIFF ONCOLOGY INC next earnings?

The consensus EPS estimate for the next earnings of CARDIFF ONCOLOGY INC (CRDF) is -0.14 USD and the consensus revenue estimate is 86.70K USD.

What is the consensus rating for CARDIFF ONCOLOGY INC (CRDF) stock?

The consensus rating for CARDIFF ONCOLOGY INC (CRDF) is 81.4286 / 100 . This indicates that analysts generally have a positive outlook on the stock.